Anuh Pharma (506260) investor relations material

Financial and operational highlights

• FY26 revenue grew 15.66% to ₹776 Cr, driven by strong volume growth and expansion in regulated markets.

• EBITDA for FY26 was ₹67.84 Cr (+6.52%), with total production reaching 1,733 MT (+24.99%).

• Export sales contributed 46% of revenue, with significant presence in Asia, Africa, and Europe.

• EBITDA margin for FY26 was 8.56%, and net profit margin was 5.32%.

• PAT for FY26 was ₹41.05 Cr, down 13.32% YoY, with reported EPS at ₹4.10.

Strategic initiatives and growth drivers

• Successfully completed USFDA and EU GMP inspections, reinforcing global compliance.

• Focus on process innovation, cost optimization, and development of high-value niche APIs.

• Ongoing investments in compliance, operational efficiency, and capacity enhancement.

• Strategic market diversification with emphasis on exports to reduce currency risk.

• Anticipates steady annual growth rate of 15-20% going forward.

Business and product portfolio

• Major manufacturer of macrolides, anti-TB, anti-bacterial, anti-malarial, anti-hypertension, and corticosteroids.

• Product mix includes Erythromycin, Chloramphenicol, Pyrazinamide, Sulphadoxine, Ambroxol HCL, Gliclazide, and corticosteroids.

• Pipeline includes products under development such as Vonoprazon Fumarate, Pretomanid, and Edoxaban Tosylate.

• Holds market leadership in several APIs and has strong R&D capabilities.